A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Encinitas, California--(November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key...
Encinitas, California--(October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision restoration in patients with...
During this presentation we welcome, Kiora Pharmaceuticals. Kiora (Nasdaq: KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. This Company Webcast was recorded during the Lytham...
Encinitas, California--(September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage...
Encinitas, California--(August 9, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces second quarter 2024 financial results and provides an update on its pipeline of therapeutics for the treatment of retinal diseases. During the...
Encinitas, California--(August 6, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming conferences that will be available to investors by live webcast. On Tuesday August 13th, 2024 at 3:00 pm Eastern...
Encinitas, California--(July 30, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of a group of inherited retinal...
Encinitas, California--(July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer, will present at the Jones Trading Healthcare Seaside Summit on Monday, July 15 at...
Ken Gayron to Step Down as a Member of the Company's BoardEncinitas, California--(July 1, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's...
Encinitas, California--(June 25, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Roger A. Goldberg, MD, MBA, a vitreoretinal surgeon at Bay Area Retina Associates (BARA) to its Scientific Advisory Board. As an advisor, Dr. Goldberg will contribute...